Payment overview · 2025
General Payments
$940.84
46 reported records · 20 companies
Healthcare provider profile · identity verified
Saaket Gupta
Allopathic & Osteopathic Physicians|Internal Medicine · SCHENECTADY, NY · NPI 1336229392
Verified facts
What the public records show
CMS Open Payments records show Saaket Gupta received $940.84 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Soliqua 100-33 by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.78 | 17.2% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.24 | 13.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.50 | 9.2% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $83.78 | 8.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $81.54 | 8.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.79 | 7.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.29 | 3.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $33.33 | 3.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.75 | 3.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.91 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.25 | 2.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.05 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.72 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.36 | 2.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.36 | 2.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.02 | 2.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.45 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.81 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.82 | 1.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.09 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $940.84 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.50 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.50 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $83.78 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.34 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $81.54 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.53 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.89 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.25 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 150 |
| Omeprazole | Omeprazole | 412 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 74 |
| Losartan Potassium | Losartan Potassium | 319 | 83 |
| Eliquis | Apixaban | 296 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 74 |
| Gabapentin | Gabapentin | 291 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 50 |
| Irbesartan | Irbesartan | 182 | 49 |
| Metformin Hcl | Metformin Hcl | 168 | 43 |
| Valsartan | Valsartan | 165 | 46 |
| Simvastatin | Simvastatin | 163 | 42 |
| Lisinopril | Lisinopril | 154 | 41 |
| Metformin Hcl Er | Metformin Hcl | 149 | 42 |
| Trazodone Hcl | Trazodone Hcl | 145 | 34 |
| Furosemide | Furosemide | 141 | 35 |
| Sertraline Hcl | Sertraline Hcl | 135 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 50 |
| Tramadol Hcl | Tramadol Hcl | 131 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 28 |
| Ozempic | Semaglutide | 120 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 31 |
| Allopurinol | Allopurinol | 113 | 28 |
| Finasteride | Finasteride | 109 | 26 |
| Atenolol | Atenolol | 108 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 33 |
| Glipizide Er | Glipizide | 99 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 24 |
| Jardiance | Empagliflozin | 89 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 16 |
| Famotidine | Famotidine | 73 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 17 |
| Januvia | Sitagliptin Phosphate | 70 | 14 |
| Prednisone | Prednisone | 70 | 47 |
| Torsemide | Torsemide | 69 | 19 |
| Alprazolam | Alprazolam | 65 | 27 |
| Potassium Chloride | Potassium Chloride | 65 | 25 |
| Celecoxib | Celecoxib | 62 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 14 |
| Lorazepam | Lorazepam | 56 | 30 |
| Alendronate Sodium | Alendronate Sodium | 55 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 16 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Glipizide | Glipizide | 52 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Montelukast Sodium | Montelukast Sodium | 52 | 12 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 16 |
| Azithromycin | Azithromycin | 49 | 42 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 21 |
| Nystatin | Nystatin | 47 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Acetic Acid | Acetic Acid | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 11 |
| Cephalexin | Cephalexin | 42 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 40 |
| Carvedilol | Carvedilol | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | 17 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 39 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Gemtesa | Vibegron | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 24 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 18 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Repaglinide | Repaglinide | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 16 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Naproxen | Naproxen | 19 | 11 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Ramipril | Ramipril | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $940.84 · 46 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, EVENITY, FREESTYLE LIBRE 3, Flector, INGREZZA, JARDIANCE, KISUNLA, Licart, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, UNITHROID, VOQUEZNA, Veozah, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error